Increased CSF APPs-a levels in patients with Alzheimer disease treated with acitretin

Neurology

Volumn 83, Issue 21, 2014, Pages 1930-1935

  Endres, Kristina ^a   Fahrenholz, Falk ^a   Lotz, Johannes ^b   Hiemke, Christoph ^a   Teipel, Stefan ^c,d   Lieb, Klaus ^a   Tüscher, Oliver ^a   Fellgiebel, Andreas ^a  

^a Department of Psychiatry and Psychotherapy Institute for Clinical Chemistry   (United States)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c Department of Psychosomatic Medicine University Medical Centre Rostock   (United States)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SECRETASE; ALPHA SECRETASE DERIVED AMYLOID PRECURSOR PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ETRETIN; PLACEBO; TAU PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; SECRETASE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAIR LOSS; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; SKIN EXFOLIATION; XEROSTOMIA; MIDDLE AGED; PILOT STUDY; TREATMENT OUTCOME;

ACITRETIN; AGED; ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84922480757     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001017     Document Type: Article

References (25)

1. Kuhn PH, Wang H, Dislich B, et al. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J 2010;29:3020-3032.
2. Postina R, Schroeder A, Dewachter I, et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 2004;113:1456-1464.
3. Anderson JJ, Holtz G, Baskin PP, et al. Reduced cerebro-spinal fluid levels of alpha-secretase-cleaved amyloid precursor protein in aged rats: correlation with spatial memory deficits. Neuroscience 1999;93:1409-1420.
4. Endres K, Fahrenholz F. Regulation of alpha-secretase ADAM10 expression and activity. Exp Brain Res 2012; 217:343-352.
5. Almkvist O, Basun H, Wagner SL, Rowe BA, Wahlund LO, Lannfelt L. Cerebrospinal fluid levels of alpha-secretase-cleaved soluble amyloid precursor protein mirror cognition in a Swedish family with Alzheimer disease and a gene mutation. Arch Neurol 1997;54:641-644.
6. Tippmann F, Hundt J, Schneider A, Endres K, Fahrenholz F. Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J 2009;23:1643-1654.
7. Armstrong JL, Ruiz M, Boddy AV, Redfern CP, Pearson AD, Veal GJ. Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells. Br J Cancer 2005;92:696-704.
8. Piaserico S, Conti A, Console FL, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol 2014;94:293-297.
9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
10. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-269.
11. Holthoewer D, Endres K, Schuck F, Hiemke C, Schmitt U, Fahrenholz F. Acitretin, an enhancer of alpha-secretase expression, crosses the blood-brain barrier and is not eliminated by P-glycoprotein. Neurodegener Dis 2012;10:224-228.
12. Chandler MJ, Lacritz LH, Hynan LS, et al. A total score for the CERAD neuropsychological battery. Neurology 2005;65:102-106.
13. Yakushev I, Muller MJ, Buchholz HG, et al. Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer's disease. Curr Alzheimer Res 2012;9:241-247.
14. Ormerod AD. Switching biologics for psoriasis. Br J Dermatol 2010;163:667-669.
15. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro. Exp Neurol 2004; 189:380-392.
16. Takasaki J, Ono K, Yoshiike Y, et al. Vitamin A has anti-oligomerization effects on amyloid-beta in vitro. J Alzheimers Dis 2011;27:271-280.
17. Ding Y, Qiao A, Wang Z, et al. Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. J Neurosci 2008;28:11622-11634.
18. Jorissen E, Prox J, Bernreuther C, et al. The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex. J Neurosci 2010;30:4833-4844.
19. Gabelle A, Roche S, Geny C, et al. Correlations between soluble alpha/beta forms of amyloid precursor protein and Abeta38, 40, and 42 in human cerebrospinal fluid. Brain Res 2010;1357:175-183.
20. Lewczuk P, Kamrowski-Kruck H, Peters O, et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry 2010;15:138-145.
21. Claasen AM, Guevremont D, Mason-Parker SE, et al. Secreted amyloid precursor protein-alpha upregulates syn-aptic protein synthesis by a protein kinase G-dependent mechanism. Neurosci Lett 2009;460:92-96.
22. Bour A, Little S, Dodart JC, Kelche C, Mathis C. A secreted form of the beta-amyloid precursor protein (sAPP695) improves spatial recognition memory in OF1 mice. Neurobiol Learn Mem 2004;81:27-38.
23. Ring S, Weyer SW, Kilian SB, et al. The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electro-physiological abnormalities of APP-deficient mice. J Neurosci 2007;27:7817-7826.
24. Taylor CJ, Ireland DR, Ballagh I, et al. Endogenous secreted amyloid precursor protein-alpha regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory. Neurobiol Dis 2008; 31:250-260.
25. Weyer SW, Zagrebelsky M, Herrmann U, et al. Comparative analysis of single and combined APP/APLP knock outs reveals reduced spine density in APP-KO mice that is prevented by APPsalpha expression. Acta Neuropathol Commun 2014;2:36.